Ivabradine: Difference between revisions – Wikipedia
}}
}}
”’Ivabradine”’, sold under the brand name ”’Procoralan”’ among others, is a [[medication]], which is a [[pacemaker current]] (I”f”) inhibitor, used for the symptomatic management of [[angina|heart-related chest pain]] and [[heart failure]]. Patients who qualify for use of Ivabradine for coronary heart failure are patients who have symptomatic heart failure, with reduced ejection volume, and heart rate at least 70 bpm, and the condition not able to be fully managed by [[beta blockers]].{{cite journal|last1=Yancy|first1=CW|last2=Jessup|first2=M|last3=Bozkurt|first3=B|last4=Butler|first4=J|last5=Casey|first5=DE Jr|last6=Colvin|first6=MM|last7=Drazner|first7=MH|last8=Filippatos|first8=G|last9=Fonarow|first9=GC|last10=Givertz|first10=MM|last11=Hollenberg|first11=SM|last12=Lindenfeld|first12=J|last13=Masoudi|first13=FA|last14=McBride|first14=PE|last15=Peterson|first15=PN|last16=Stevenson|first16=LW|last17=Westlake|first17=C|title=2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.|journal=Circulation|date=20 May 2016|pmid=27208050|doi=10.1161/CIR.0000000000000435|volume=134|issue=13|pages=e282–e293|doi-access=free}}
”’Ivabradine”’, sold under the brand name ”’Procoralan”’ among others, is a [[medication]], which is a [[pacemaker current]] (I”f”) inhibitor, used for the symptomatic management of [[angina|heart-related chest pain]] and [[heart failure]]. Patients who qualify for use of Ivabradine for coronary heart failure are patients who have symptomatic heart failure, with reduced ejection volume, and heart rate at least 70 bpm, and the condition not able to be fully managed by [[beta blockers]].{{cite journal|=YancyCWJessupMBozkurtBButlerJCaseyDE ColvinMMDraznerMHFilippatosGFonarowGCGivertzMMHollenbergSMLindenfeldJMasoudiFAMcBridePEPetersonPNStevensonLWWestlake|=|title=2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America|journal=Circulation|date= 2016|pmid=27208050|doi=10.1161/CIR.0000000000000435|doi-access=free}}
Ivabradine acts by allowing negative chronotropy in the sinoatrial structure thus reducing the [[heart rate]] via specific inhibition of the [[pacemaker current]], a mechanism different from that of [[beta blocker]]s and [[calcium channel blocker]]s, two commonly prescribed [[antianginal]] classes of cardiac pharmaceuticals. Ivabradine has no apparent inotropic properties and may be a cardiotonic agent.
Ivabradine acts by allowing negative chronotropy in the sinoatrial structure thus reducing the [[heart rate]] via specific inhibition of the [[pacemaker current]], a mechanism different from that of [[beta blocker]]s and [[calcium channel blocker]]s, two commonly prescribed [[antianginal]] classes of cardiac pharmaceuticals. Ivabradine has no apparent inotropic properties and may be a cardiotonic agent.
==Medical uses==
==Medical uses==
It is used for the symptomatic treatment of chronic stable [[angina pectoris]] in patients with normal [[sinus rhythm]] who cannot take [[beta blockers]]. It is also being used off-label in the treatment of [[inappropriate sinus tachycardia]].{{cite journal |vauthors=Yusuf S, Camm AJ |title=Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? |journal=J. Cardiovasc. Pharmacol. Ther. |volume=8 |issue=2 |pages=89–105 |year=2003 |pmid=12808482|doi=10.1177/107424840300800202|s2cid=25305128 }} Ivabradine stands as a pharmacological option for controlling HR and rhythm without associated side effects in postoperative CABG patients with IST{{Cite journal|last1=Bhatt|first1=Parloop|last2=Bhavsar|first2=Niren|last3=Naik|first3=Dhaval|last4=Shah|first4=Dhiren|date=2021-07-01|title=Comparative effectiveness of metoprolol, ivabradine, and its combination in the management of inappropriate sinus tachycardia in coronary artery bypass graft patients|url=https://www.ijp-online.com/article.asp?issn=0253-7613;year=2021;volume=53;issue=4;spage=264;epage=269;aulast=Bhatt;type=0|journal=Indian Journal of Pharmacology|language=en|volume=53|issue=4|pages=264–269|doi=10.4103/ijp.IJP_478_19|doi-broken-date=1 August 2023|pmid=34414903|pmc=8411959|issn=0253-7613}}
It is used for the symptomatic treatment of chronic stable [[angina pectoris]] in patients with normal [[sinus rhythm]] who cannot take [[beta blockers]]. It is also being used off-label in…
Read More: Ivabradine: Difference between revisions – Wikipedia